| Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson's disease: a randomised, controlled, double-blind, double-dummy study CW Olanow, K Kieburtz, P Odin, AJ Espay, DG Standaert, HH Fernandez, ... The Lancet Neurology 13 (2), 141-149, 2014 | 778 | 2014 |
| Current concepts in diagnosis and treatment of functional neurological disorders AJ Espay, S Aybek, A Carson, MJ Edwards, LH Goldstein, M Hallett, ... JAMA neurology 75 (9), 1132-1141, 2018 | 681 | 2018 |
| Technology in Parkinson's disease: challenges and opportunities AJ Espay, P Bonato, FB Nahab, W Maetzler, JM Dean, J Klucken, ... Movement Disorders 31 (9), 1272-1282, 2016 | 677 | 2016 |
| Effects of admission hyperglycemia on mortality and costs in acute ischemic stroke LS Williams, J Rotich, R Qi, N Fineberg, A Espay, A Bruno, SE Fineberg, ... Neurology 59 (1), 67-71, 2002 | 671 | 2002 |
| Association of Cerebrospinal Fluid β-Amyloid 1-42, T-tau, P-tau181, and α-Synuclein Levels With Clinical Features of Drug-Naive Patients With Early Parkinson … JH Kang, DJ Irwin, AS Chen-Plotkin, A Siderowf, C Caspell, CS Coffey, ... JAMA neurology 70 (10), 2013 | 454 | 2013 |
| Motor cortex plasticity in Parkinson's disease and levodopa-induced dyskinesias F Morgante, AJ Espay, C Gunraj, AE Lang, R Chen Brain 129 (4), 1059-1069, 2006 | 382 | 2006 |
| Disease modification in Parkinson's disease: current approaches, challenges, and future considerations AE Lang, AJ Espay Movement Disorders 33 (5), 660-677, 2018 | 371 | 2018 |
| Cognitive performance and neuropsychiatric symptoms in early, untreated Parkinson's disease D Weintraub, T Simuni, C Caspell‐Garcia, C Coffey, S Lasch, A Siderowf, ... Movement Disorders 30 (7), 919-927, 2015 | 353 | 2015 |
| Levodopa‐induced dyskinesia in Parkinson disease: current and evolving concepts AJ Espay, F Morgante, A Merola, A Fasano, L Marsili, SH Fox, E Bezard, ... Annals of Neurology 84 (6), 797-811, 2018 | 335 | 2018 |
| A recurrent de novo mutation in KCNC1 causes progressive myoclonus epilepsy M Muona, SF Berkovic, LM Dibbens, KL Oliver, S Maljevic, MA Bayly, ... Nature genetics 47 (1), 39-46, 2015 | 334 | 2015 |
| Norepinephrine deficiency in Parkinson's disease: the case for noradrenergic enhancement AJ Espay, PA LeWitt, H Kaufmann Movement Disorders 29 (14), 1710-1719, 2014 | 271 | 2014 |
| A roadmap for implementation of patient‐centered digital outcome measures in Parkinson's disease obtained using mobile health technologies AJ Espay, JM Hausdorff, Á Sánchez‐Ferro, J Klucken, A Merola, P Bonato, ... Movement Disorders 34 (5), 657-663, 2019 | 263 | 2019 |
| Long-term unsupervised mobility assessment in movement disorders E Warmerdam, JM Hausdorff, A Atrsaei, Y Zhou, A Mirelman, K Aminian, ... The Lancet Neurology 19 (5), 462-470, 2020 | 262 | 2020 |
| Levodopa‐carbidopa intestinal gel in advanced Parkinson's disease: final 12‐month, open‐label results HH Fernandez, DG Standaert, RA Hauser, AE Lang, VSC Fung, ... Movement Disorders 30 (4), 500-509, 2015 | 259 | 2015 |
| “On” state freezing of gait in Parkinson disease: a paradoxical levodopa-induced complication AJ Espay, A Fasano, BFL Van Nuenen, MM Payne, AH Snijders, ... Neurology 78 (7), 454-457, 2012 | 250 | 2012 |
| APOE, MAPT, and SNCA genes and cognitive performance in Parkinson disease IF Mata, JB Leverenz, D Weintraub, JQ Trojanowski, HI Hurtig, ... JAMA neurology 71 (11), 1405-1412, 2014 | 246 | 2014 |
| GBA Variants are associated with a distinct pattern of cognitive deficits in Parkinson's disease IF Mata, JB Leverenz, D Weintraub, JQ Trojanowski, A Chen‐Plotkin, ... Movement Disorders 31 (1), 95-102, 2016 | 234 | 2016 |
| The modified bradykinesia rating scale for Parkinson's disease: reliability and comparison with kinematic measures DA Heldman, JP Giuffrida, R Chen, M Payne, F Mazzella, AP Duker, ... Movement Disorders 26 (10), 1859-1863, 2011 | 227 | 2011 |
| Inosine to increase serum and cerebrospinal fluid urate in Parkinson disease: a randomized clinical trial MA Schwarzschild, A Ascherio, MF Beal, ME Cudkowicz, GC Curhan, ... JAMA neurology 71 (2), 141-150, 2014 | 226 | 2014 |
| Extended-release carbidopa-levodopa (IPX066) compared with immediate-release carbidopa-levodopa in patients with Parkinson's disease and motor fluctuations: a phase 3 … RA Hauser, A Hsu, S Kell, AJ Espay, K Sethi, M Stacy, W Ondo, ... The Lancet Neurology 12 (4), 346-356, 2013 | 225 | 2013 |